Arcus Biosciences Stock Z Score
| RCUS Stock | USD 15.50 0.82 5.59% |
Arcus | Z Score |
Arcus Biosciences Company Z Score Analysis
Arcus Biosciences' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Arcus Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Arcus Biosciences is extremely important. It helps to project a fair market value of Arcus Stock properly, considering its historical fundamentals such as Z Score. Since Arcus Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arcus Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arcus Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
Based on the company's disclosures, Arcus Biosciences has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Arcus Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arcus Biosciences' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arcus Biosciences could also be used in its relative valuation, which is a method of valuing Arcus Biosciences by comparing valuation metrics of similar companies.Arcus Biosciences is currently under evaluation in z score category among related companies.
Arcus Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Arcus Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Arcus Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Arcus Biosciences' value.| Shares | Goldman Sachs Group Inc | 2023-12-31 | 1.2 M | Geode Capital Management, Llc | 2023-12-31 | 1.1 M | Woodline Partners Lp | 2023-12-31 | 1 M | Suvretta Capital Management, Llc | 2023-12-31 | 957.3 K | Decheng Capital Llc | 2023-12-31 | 869.8 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 701.4 K | Bnp Paribas Investment Partners Sa | 2023-12-31 | 539.7 K | Northern Trust Corp | 2023-12-31 | 524.7 K | Balyasny Asset Management Llc | 2023-12-31 | 515.5 K | Blackrock Inc | 2023-12-31 | 10 M | Fmr Inc | 2023-12-31 | 4.7 M |
Arcus Fundamentals
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (2.62) % | ||||
| Operating Margin | (2.94) % | ||||
| Current Valuation | 695.9 M | ||||
| Shares Outstanding | 90.86 M | ||||
| Shares Owned By Insiders | 41.17 % | ||||
| Shares Owned By Institutions | 59.80 % | ||||
| Number Of Shares Shorted | 8.25 M | ||||
| Price To Earning | 27.69 X | ||||
| Price To Book | 3.26 X | ||||
| Price To Sales | 12.88 X | ||||
| Revenue | 117 M | ||||
| Gross Profit | (176 M) | ||||
| EBITDA | (291 M) | ||||
| Net Income | (307 M) | ||||
| Cash And Equivalents | 1.05 B | ||||
| Cash Per Share | 14.48 X | ||||
| Total Debt | 11 M | ||||
| Debt To Equity | 0.17 % | ||||
| Current Ratio | 6.22 X | ||||
| Book Value Per Share | 6.12 X | ||||
| Cash Flow From Operations | (306 M) | ||||
| Short Ratio | 10.54 X | ||||
| Earnings Per Share | (4.15) X | ||||
| Target Price | 39.2 | ||||
| Number Of Employees | 577 | ||||
| Beta | 0.85 | ||||
| Market Capitalization | 1.33 B | ||||
| Total Asset | 1.09 B | ||||
| Retained Earnings | (849 M) | ||||
| Working Capital | 647 M | ||||
| Net Asset | 1.09 B |
About Arcus Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arcus Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcus Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcus Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Arcus Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Arcus Biosciences' short interest history, or implied volatility extrapolated from Arcus Biosciences options trading.
Currently Active Assets on Macroaxis
When determining whether Arcus Biosciences is a strong investment it is important to analyze Arcus Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Arcus Biosciences' future performance. For an informed investment choice regarding Arcus Stock, refer to the following important reports:Check out Arcus Biosciences Piotroski F Score and Arcus Biosciences Valuation analysis. For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Arcus Stock analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
Is Arcus Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcus Biosciences. If investors know Arcus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcus Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.15) | Revenue Per Share 1.581 | Quarterly Revenue Growth (0.09) | Return On Assets (0.17) | Return On Equity (0.55) |
The market value of Arcus Biosciences is measured differently than its book value, which is the value of Arcus that is recorded on the company's balance sheet. Investors also form their own opinion of Arcus Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcus Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcus Biosciences' market value can be influenced by many factors that don't directly affect Arcus Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcus Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcus Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcus Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.